Caroline Claar, NP
Primary Care · Atlanta, GANPI 1942673322
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 126 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 21.7% — the pattern of someone who eats at a lot of different presentations.
Across 126 payments — averaging $22.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$604
- Lundbeck LLC$288
- Eisai Inc.$262
- UCB, Inc.$235
- Novartis$226
- Axsome Therapeutics, Inc.$163
- plus $1K from 21 others
What the payments were for
- Food & beverage$2,785100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 40 | $604 |
| Lundbeck LLC | 12 | $288 |
| Eisai Inc. | 7 | $262 |
| UCB, Inc. | 10 | $235 |
| Novartis | 9 | $226 |
| Axsome Therapeutics, Inc. | 6 | $163 |
| Otsuka America Pharmaceutical, Inc. | 5 | $125 |
| Biogen | 5 | $121 |
| Teva Pharmaceuticals USA, Inc. | 5 | $113 |
| Neurocrine Biosciences, Inc. | 3 | $93 |
| AstraZeneca(2 entities) | 3 | $70 |
| SK Life Science, Inc. | 2 | $59 |
| Lilly USA, LLC | 2 | $57 |
| Merz Pharmaceuticals, LLC | 2 | $41 |
| Neurelis, Inc. | 1 | $40 |
| Amneal Pharmaceuticals LLC | 2 | $38 |
| Scilex Pharmaceuticals Inc. | 2 | $37 |
| Argenx US, Inc. | 1 | $31 |
| GE HealthCare | 1 | $28 |
| Jazz Pharmaceuticals Inc. | 1 | $26 |
| Genentech USA, Inc. | 1 | $23 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
| Johnson & Johnson | 1 | $22 |
| MDD US Operations, LLC | 1 | $19 |
| Acadia Pharmaceuticals Inc | 1 | $16 |
| EMD Serono, Inc. | 1 | $14 |
| Cycle Pharmaceuticals Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Leqembi$125
How this compares
$2,785 in reported general payments places this provider in the 80th percentile of 235 primary care providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 32 | $23,954 |
| Anastrozole | 45 | $817 |
| Letrozole | 27 | $472 |
Paid to pharmacies, not to this prescriber.
Other primary care in Atlanta
- Erin EverettAtlanta$7K
- Erin BartonAtlanta$6K
- Natasha WilliamsonAtlanta$5K
- Lauren BolleAtlanta$4K
- Karen GuidryAtlanta$3K
- Pamela TurkDouglas$15K
- Morgan JonesLawrenceville$14K
- Jessi HaleColumbus$13K
- Meredith CarrAugusta$12K
- Ashtyn ZaryckiSavannah$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.